# Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

> **NCT00974311** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1199 (actual)

## Conditions studied

- Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00974311
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-30
- **Primary completion:** 2011-09-15
- **Final completion:** 2017-11-02
- **Target enrollment:** 1199 (ACTUAL)
- **Last updated:** 2018-12-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00974311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00974311, "Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00974311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*